

Special Issue

Immunotherapy and Vaccine Development for Viral Diseases

Message from the Guest Editors

Antiviral therapy through vaccines has saved countless lives and kept outbreaks and pandemics like smallpox, influenza and COVID-19 under check. The immune system can target any pathogen, yet we still become infected with novel infectious agents throughout our lives. An exhaustive catalog of factors from hosts and pathogens that underpin whether an infection triggers or suppresses an immune response is needed to facilitate targeted therapy and reliable prognosis. In addition to reports on vaccine discovery and development, we seek basic research on the roles of viral proteins in immune response during infection and the cellular machineries these viral proteins regulate in reproduction, virulence and dormancy for improved vaccine and immunotherapies. Submissions on the discovery, development and reviews of biologics like the antibodies used in immunotherapy will also be considered for inclusion in this Special Issue. Reports on small molecules and natural products that facilitate immune activation or suppression during viral infections are also welcome.

Guest Editors

Dr. Emmanuel Datan

Vascular Program, Institute for Cell Engineering and Department of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Prof. Dr. Athanasios Tsakris

Department of Microbiology, Medical School University of Athens, Athens, Greece

Deadline for manuscript submissions

closed (28 February 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/190864

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).